Opthea Revenue and Competitors

South Yarra, AU

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Opthea's estimated annual revenue is currently $11M per year.(i)
  • Opthea's estimated revenue per employee is $155,000

Employee Data

  • Opthea has 71 Employees.(i)
  • Opthea grew their employee count by 61% last year.

Opthea's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CEOReveal Email/Phone
3
Chief Financial OfficerReveal Email/Phone
4
Chief Medical OfficerReveal Email/Phone
5
Chief Commercial Officer (CCO)Reveal Email/Phone
6
Chief Financial OfficerReveal Email/Phone
7
Chief Financial OfficerReveal Email/Phone
8
VP CMCReveal Email/Phone
9
SVP, Global Clinical OperationsReveal Email/Phone
10
VP Market AccessReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$116.6M752-23%N/AN/A
#2
$42.3M273N/AN/AN/A
#3
$15.3M994%N/AN/A
#4
$17.8M11513%N/AN/A
#5
$19.7M12717%N/AN/A
#6
$26.8M17319%N/AN/A
#7
$16.6M107-15%N/AN/A
#8
$12.7M82-29%N/AN/A
#9
$9.7M102-15%$412.3MN/A
#10
$25.9M1677%N/AN/A
Add Company

What Is Opthea?

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases, including wet age‐related macular degeneration (wet AMD) and diabetic macular edema (DME), which remain leading causes of vision loss worldwide. \n\nOpthea’s lead product candidate in Phase 3 development, sozinibercept, is a first-in-class VEGF-C/D ‘trap’ inhibitor being evaluated in combination with standard-of-care anti-VEGF-A therapies to deliver superior vision to wet AMD patients. Sozinibercept has the potential to become the first therapy in 20 years to enable patients with wet AMD to live fuller and healthier lives.

keywords:N/A

N/A

Total Funding

71

Number of Employees

$11M

Revenue (est)

61%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$25.1M7257%N/A
#2
$21.3M7922%N/A
#3
$12M80-18%N/A
#4
$12.8M8533%N/A
#5
$17.4M85-20%N/A